Athens Research & Technology Inc.

Established in 1986, the company has built a reputation for excellence in the quality of native proteins with high purity, offering a diverse research community of international diagnostic and pharmaceutical industry, academic research labs, the protein and enzyme reagent components to be used for in vitro diagnostics and immunoassay kits, as well as cell culture media application.

They have proven success in diagnostic assay development applications including Lipoproteins and Globulin Panel, HaemoglobinAc1 Standards and targeted disease tests for cardiovascular, pulmonary and autoimmune disorders.

Recognising that each diagnostic solutions can be unique, they have expanded their services to offer highly customised protein purification services and bulk protein development ensuring that these proteins efficiently integrate with various diagnostic assays and workflows. 

Athens makes every effort to retain active native protein structure and post-translational modifications, so it remains as it exists in the source tissue. Protocols are developed and tested to minimise deglycosylation and aggregation, and the technical support team ensures that customers receive all the answers specific to purification questions. 

With 39 years of experience as a high-quality native protein vendor they provide and offer 

• Custom services for Native Protein isolation from animal sera and tissues 
• Accomplished in the purification of proteins from other species and in the preparation of biotherapeutics for proof-of-concept studies in animal models.
• Range of Culture media growth supplements for Tissue Culture Grade ≥95% pure and ≤0.1 EU/mg and Bio-processing Grade - ≥98%pure, <1 EU/mg, <10 CFU/mg, and Heat Treated
• High purity Proteins for cellular function assessment 
• Proteins for Quality Control as standard calibration and control for cardiology, nephrology, diabetes and other disease state optimisation, for example they contribute to HDL and LDL cholesterol test panels.
• They have been primary suppliers for enzymes and inhibitors associated with blood disorders
• Antisera and positive controls for future Lateral Flow test commercialization are available

Research on Apolipoprotein A1 (ApoA1) in ALS

A recent study from the University of South Florida (eNeuro, 2022) links dyslipidaemia (alternated lipid metabolism) to neurodegeneration, highlighting ApoA1 as a possible therapeutic pathway for amyotrophic lateral sclerosis (ALS).

Researchers demonstrated that ApoA1 shielded brain endothelial cells from ALS-like plasma damage using Athens Research & Technology's Low Endotoxin Level ApoA1 (Cat# 16-16-120101-LEL), suggesting new therapeutic potential.

Why this is important for researchers:

• Dyslipidemia's role in ALS and neurodegeneration is becoming more widely acknowledged.
• Therapeutic Insight: ApoA1 may offer protection to the brain in addition to the heart.

Uses:

• ALS, neurodegeneration, and lipid metabolism research labs at universities
• Use of IVD (biomarker, calibrator/control in test kits)
• BioTech & Pharma (biotherapeutics pipeline candidate)

New insights on Oxidative Stress and COPD

Lipid-laden macrophages (LLMs) and oxidative stress have been linked to COPD, the third most common cause of death globally, according to a recent Redox Biology study (University of Georgia, 2025).

A crucial ingredient in this ground-breaking study was purified oxidised LDL (Cat# 12-16-120412-OX) from Athens Research & Technology, which allowed for both animal and cell-based assays.

The significance of this for researchers

• Global Impact: Over 400 million people worldwide suffer from COPD.
• New Mechanisms: In COPD, asthma, and cardiovascular disease, LLMs are now connected to inflammation and lung damage.

 Uses:

• University studies on inflammation, diabetes, atherosclerosis, COPD, and asthma
• IVD sector (OxLDL as biomarker; test kit calibrator/control)
• Pharma R&D (therapeutic targets in diabetes, lipid metabolism, cardiovascular disease, and COPD)